Drugs / Genistein
Trials 27 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00276835 | Nov 2005 → Jul 2007 | cutaneous melanoma, kidney cancer | Northwestern University | Completed | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT06741345 | Dec 2024 → Aug 2025 | — | Humanetics Corporation | Completed | No outcome recorded |
| Phase 1 | NCT04650555 | Dec 2020 → Jul 2021 | acute radiation syndrome | Humanetics Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02075112 | Nov 2013 → Sep 2019 | head and neck cancer | Emory University | Completed | No outcome recorded |
| Phase 1 | NCT00504335 | Jun → Sep 2007 | acute radiation syndrome | Humanetics Corporation | Completed | No outcome recorded |
| Phase 1 | NCT00001696 | Apr 1998 → Mar 2001 | cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/28 trials | ||||||
| Phase 1/2 | NCT07033767 | Aug 2025 → Aug 2026 overdue | obesity disorder | Western University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06634108 | Sep 2024 → Sep 2025 overdue | amyloidosis | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06501768 | Jul 2024 → Jul 2026 overdue | heart failure | University Medical Centre Ljubljana | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02567799 | Nov 2015 → Apr 2019 | non-small cell lung carcinoma | Humanetics Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT02499861 | Jul 2015 → Oct 2017 | cancer | St. Justine's Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT01985763 | Nov 2013 → Jan 2017 | colon carcinoma, rectal carcinoma | Sofya Pintova | Completed | No outcome recorded |
| Phase 1/2 | NCT01628471 | Nov 2012 → May 2015 | non-small cell lung carcinoma | Uman Pharma | Completed | No outcome recorded |
| Phase 1/2 | NCT01182246 | Nov 2010 → Mar 2016 | adenocarcinoma | Axcentua Pharmaceuticals AB | Unknown | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT07323732 | Jan 2026 → Jan 2029 expected | interstitial lung disease, non-small cell lung carcinoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04482595 | Nov 2020 → Jul 2024 | COVID-19, long COVID-19, pulmonary fibrosis | Humanetics Corporation | Unknown | No outcome recorded |
| Phase 2 | NCT02766478 | Oct 2017 → Jul 2021 | prostate cancer | Emory University | Terminated | No outcome recorded |
| Phase 2 | NCT01489813 | May 2017 → Aug 2023 | urinary bladder cancer | Emory University | Completed | No outcome recorded |
| Phase 2 | NCT02624388 | Aug 2016 → Sep 2021 | Ewing sarcoma, Hodgkins lymphoma, Wilms tumor, childhood medulloblastoma +5 | University of Virginia | Terminated | No outcome recorded |
| Phase 2 | NCT01325311 | Dec 2011 → Jul 2014 | prostate adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00290758 | Jan 2006 → Mar 2009 | breast cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00118040 | Jun 2005 → Aug 2010 | urinary bladder carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01553773 | Jul 2004 → Mar 2005 | muscular atrophy | Federal University of São Paulo | Completed | No outcome recorded |
| Phase 2 | NCT00000613 | Apr 1997 → Dec 2004 | coronary artery disorder, depressive disorder, myocardial ischemia, osteoporosis | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT00355953 | Jan 2003 → Jun 2005 | — | University of Messina | Completed | No outcome recorded |
| Phase 2/3 | NCT00287690 | Oct 1999 → Aug 2003 | coronary artery disorder | Imperial College London | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01497977 | Sep 2008 → Jun 2010 | hypolipoproteinemia | American Medical Academy, Serbia | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00590538 Comparator | Feb 2003 → Dec 2008 | cystic fibrosis | Children's Hospital of Philadelphia | Terminated | No outcome recorded |
| Phase 1/2 | NCT00016744 Comparator | Sep 2001 → Oct 2005 | cystic fibrosis | Children's Hospital of Philadelphia | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00546039 Comparator | Apr 2007 → Aug 2008 | prostate cancer | University Hospital, Aker | Unknown | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 31 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Genistein | “Starting on day 10 and continuing through day 19, genistein will be administered orally at a dose of 600mg/day in two divided doses (i.e. 300mg po bid x 10 days)” NCT00276835 ↗25“A Pilot Study of Soy Isoflavone, Genistein, in Combination With Radiation Therapy and Cisplatin in Locally Advanced Squamous Cell Carcinoma of the Head and Neck” NCT02075112 ↗ “Genistein HME was evaluated in a phase 1, open-label, single ascending dose (SAD) and multiple single dose (MSD) study enrolling 34 healthy volunteers.” PMID 36301689 ↗ Oct 2022 “BIO 300 Oral Suspension (genistein 1500 mg) will be self-administered daily for 7 days each week for 12 weeks.” NCT04482595 ↗ “The soya daily dose contained 2 isoflavones: genistein (39mg) and daidzein (1mg).” NCT01497977 ↗ “a gel with isoflavones (genistein 4%)” NCT01553773 ↗ “Genistein” NCT02075112 ↗ |
| Known as | AXP107-11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01182246 ↗ |
| Known as | BIO 300 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00504335 ↗ |
| Known as | G-2535 | “A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients.” PMID 22293631 ↗ Jan 2012 |
| Known as | Soy isoflavone | “A Pilot Study of Soy Isoflavone, Genistein, in Combination With Radiation Therapy and Cisplatin in Locally Advanced Squamous Cell Carcinoma of the Head and Neck” NCT02075112 ↗ |
| Action | Inhibit | “Genistein is a known protein-tyrosine kinase inhibitor” NCT00001696 ↗ |
| Modality | Other / unclassified | “Genistein is a phytoestrogen of the isoflavone family which has been shown to have beneficial effects on endothelial function and bone metabolism.” NCT00355953 ↗ |
| Route | Topical | “topical application of genistein to the nasal mucosa during the NPD procedure on study days 1 and 7.” NCT00016744 ↗ |
| Target | TTR | “genistein has been shown to bind and stabilize TTR, potentially inhibiting its misfolding and subsequent fibril formation.” NCT06634108 ↗ |